Phase 2 Mesothelioma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are generally able to carry out daily activities without much difficulty (good physical functioning, confirmed with trial site)
• You have been diagnosed with a type of cancer affecting the lining of the lung (malignant pleural mesothelioma) that cannot be removed by surgery
• Your cancer has come back or progressed after 1 or 2 rounds of standard chemotherapy, OR you are unable to have chemotherapy or have chosen not to have it
• You are already being considered for a procedure involving a camera examination of the chest cavity (thoracoscopy) to help manage fluid buildup
• Your cancer can be seen and measured on scans using standard criteria for this type of cancer
• The cancer areas in the chest lining are in a position where a light-based treatment (photodynamic therapy/PDT) can be applied during the chest procedure (confirm with trial site)
• Your diagnosis has been confirmed by a specialist national panel of cancer pathologists
• You have lost less than 10% of your body weight
• There is tumor tissue available (either recently collected or stored from a previous biopsy)
• You have given written consent to take part before any study procedures begin
• Your case has been reviewed and approved by a specialist mesothelioma medical team in France
• You are covered by French social security for standard care
• If you are a woman who could become pregnant, you must use a highly effective form of contraception starting 28 days before the first treatment and continuing for 5 months after the last dose
• If you are a woman who could become pregnant, you must have a negative pregnancy test within 24 hours before receiving the study treatment

Who may not be able to join:

• You are unwilling or unable to give written informed consent to take part
• You are pregnant, breastfeeding, or are a woman who could become pregnant and are unwilling or unable to use effective contraception during the study and for at least 5 months after the last dose of the study drug (nivolumab)
• You are a man who is unwilling or unable to use contraception during the study and for at least 7 months after the last dose of nivolumab
• You have previously been treated with a type of immunotherapy drug called an anti-PD-1 or anti-PD-L1 antibody (for this or any other cancer) in the last 5 years
• You have a known allergy or serious reaction to nivolumab
• You have a medical reason that prevents you from receiving the light-based treatment (PDT) or the drug used with it (5-ALA) (confirm with trial site)
• You have a medical reason that prevents you from having the chest camera procedure (thoracoscopy)
• You have another serious health condition that could make the treatment unsafe, such as uncontrolled heart failure, high blood pressure in the lungs, severe liver or kidney problems, or an uncontrolled infection
• You have been treated for another type of cancer within the last 5 years (exceptions may apply for certain minor skin cancers or early-stage cancers — confirm with trial site)
• You are unable to understand the study information or give informed consent
• You are unable to attend regular follow-up appointments due to personal, family, social, or location-related reasons
• You are currently in prison or are under a legal guardianship arrangement
• You have taken part in another experimental drug trial within 30 days before joining this study

Important: Always verify eligibility with the trial site directly before applying.